Phase II Rituxan CLL/SLL data

Idec (IDPH) and partner Genentech (DNA) said that in a Phase II trial of 68 patients with previously untreated advanced chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), Rituxan...